Coronavirus and Pharmaceutical Industry
In a discussion two years ago, I said that if China and India embargoed raw materials for medicines (BBO) on Indonesia, the Indonesian pharmaceutical industry would only be able to survive for six months.
The Indonesian pharmaceutical industry has no resilience because it is highly dependent on the raw material for medicines from the two countries. Indonesia's BBO imports from China is 63 percent, India 23 percent, and the rest are from other countries.
The dependence is not only on active ingredients, but also excipients (supporting materials) for the manufacture of drugs. Now, the Covid-19 pandemic has caused China and India to embargo BBO to Indonesia. The scarcity of BBO and supporting materials will have a multi-crisis impact on the national supply of medicines.